Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: Results of a prospective cohort study

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 9, 2010, Pages 1050-1057

  Melin, Pascal ^a,b   Chousterman, Michel ^c   Fontanges, Thierry ^d   Ouzan, Denis ^e   Rotily, Michel ^f   Lang, Jean Philippe ^g   Marcellin, Patrick ^h,i   Cacoub, Patrice ^j,k  

^a Hospital of Saint Dizier   (France)

^b Centre de Soins d'Accompagnement et de Prévention   (France)

^c CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^d General Hospital of Bourgoin   (Norway)

^e INSTITUT ARNAULT TZANCK   (France)

^f ClinSearch   (France)

^g Hospital of Erstein   (France)

^h BEAUJON HOSPITAL   (France)

ⁱ CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^k SORBONNE UNIVERSITÉ   (France)

more..

Author keywords

adherence; drug use; hepatitis C virus; peginterferon a 2b; ribavirin; routine clinical practice; sustained virological response

Indexed keywords

ILLICIT DRUG; OPIATE; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG USE; FEMALE; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SHORT FORM 36;

ANALGESICS, OPIOID; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; INTERFERON ALFA-2B; MEDICATION ADHERENCE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RIBAVIRIN; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 77955466100     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328338d9aa     Document Type: Article

References (17)

1. Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L. Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect 2002; 129:577-585.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567.
3. Backmund M, Meyer K,Wachtler M, Eichenlaub D. Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity. Eur J Epidemiol 2003; 18:563-568.
4. Crofts N, Jolley D, Kaldor J, van Beek I,Wodak A. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J Epidemiol Commun Health 1997; 51:692-697.
5. Galeazzi B, Tufano A, Barbierato E, Bortolotti F. Hepatitis C virus infection in Italian intravenous drug users: epidemiological and clinical aspects. Liver 1995; 15:209-212.
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
8. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40:120-124.
9. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37:443-451.
10. Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, et al. Hepatitis C treatment in difficult-to-treat psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007; 46:991-998.
11. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075.
12. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473-483.
13. Bruggmann P, Falcato L, Dober S, Helbling B, Keiser O, Negro F, et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat 2008; 15:747-752.
14. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
15. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 2007; 19:741-747.
16. Schafer A, Wittchen HU, Backmund M, Soyka M, Golz J, Siegert J, et al. Psychopathological changes and quality of life in hepatitis C virus-infected, opioid-dependent patients during maintenance therapy. Addiction 2009; 104:630-640.
17. McHutchison JG, Ware JE Jr, Bayliss MS, Pianko S, Albrecht JK, Cort S, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34:140-147.